Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $5.83.

A number of research firms recently issued reports on MIST. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Thursday, September 3rd. Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 target price for the company. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. Finally, Piper Sandler lowered their price target on Milestone Pharmaceuticals to $3.00 and set an “overweight” rating on the stock in a research report on Monday.

Check Out Our Latest Stock Report on MIST

Milestone Pharmaceuticals Stock Down 29.8%

Shares of MIST stock opened at $0.36 on Tuesday. The stock’s 50 day simple moving average is $0.79 and its 200 day simple moving average is $1.30. Milestone Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $3.06. The company has a debt-to-equity ratio of 3.25, a current ratio of 8.13 and a quick ratio of 7.92.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $1.00 million. As a group, equities research analysts forecast that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Waterloo Capital L.P. bought a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $40,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter worth $68,000. Valeo Financial Advisors LLC grew its stake in shares of Milestone Pharmaceuticals by 12.2% in the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after acquiring an additional 16,000 shares during the last quarter. RVW Wealth LLC bought a new position in Milestone Pharmaceuticals during the third quarter worth $994,000. Finally, HighTower Advisors LLC increased its position in Milestone Pharmaceuticals by 100.0% during the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

Featured Stories

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.